Caladrius Biosciences, Inc. (CLBS): Price and Financial Metrics


Caladrius Biosciences, Inc. (CLBS): $0.47

0.02 (+3.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLBS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLBS Stock Price Chart Interactive Chart >

Price chart for CLBS

CLBS Price/Volume Stats

Current price $0.47 52-week high $1.68
Prev. close $0.45 52-week low $0.40
Day low $0.45 Volume 119,300
Day high $0.48 Avg. volume 534,447
50-day MA $0.60 Dividend yield N/A
200-day MA $0.89 Market Cap 28.44M

Caladrius Biosciences, Inc. (CLBS) Company Bio


Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies.


CLBS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLBS Latest Social Stream


Loading social stream, please wait...

View Full CLBS Social Stream

Latest CLBS News From Around the Web

Below are the latest news stories about Caladrius Biosciences Inc that investors may wish to consider to help them evaluate CLBS as an investment opportunity.

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

Girolamo brings legal, finance and M&A experience to cell therapy companyMIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently servin

Yahoo | February 17, 2022

Caladrius Biosciences to Present at the BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

GlobeNewswire | February 8, 2022

Dawson James Remains a Hold on Caladrius Biosciences (CLBS)

Dawson James analyst Jason Kolbert maintained a Hold rating on Caladrius Biosciences (CLBS – Research Report) on December 10. The company's shares closed last Tuesday at $1.03, close to its 52-week low of $0.82. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The the analyst consensus on Caladrius Biosciences is currently a Hold rating.

Brian Anderson on TipRanks | January 5, 2022

Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022

BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms. Biotech Showcase (January 10–12, 2022 and January 17–19, 2022

Yahoo | January 4, 2022

Do Options Traders Know Something About Caladrius (CLBS) Stock We Don't?

Investors need to pay close attention to Caladrius (CLBS) stock based on the movements in the options market lately.

Yahoo | December 22, 2021

Read More 'CLBS' Stories Here

CLBS Price Returns

1-mo -17.54%
3-mo -35.79%
6-mo -50.24%
1-year -69.08%
3-year -84.01%
5-year -89.53%
YTD -44.15%
2021 -41.15%
2020 -43.03%
2019 -29.49%
2018 1.42%
2017 24.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.462 seconds.